tiprankstipranks
Inspire Medical Systems (INSP)
NYSE:INSP
US Market
INSP
Inspire Medical Systems
RESEARCH TOOLSreports
Want to see INSP full AI Analyst Report?

Inspire Medical Systems (INSP) Stock Forecast & Price Target

812 Followers
See the Price Targets and Ratings of:

INSP Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
4 Buy
10 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Inspire
Medical Systems
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

INSP Stock 12 Month Forecast

Average Price Target

$67.73
▲(17.60% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Inspire Medical Systems in the last 3 months. The average price target is $67.73 with a high forecast of $85.00 and a low forecast of $56.00. The average price target represents a 17.60% change from the last price of $57.59.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"$52","105":"$105","158":"$158","78.5":"$78.5","131.5":"$131.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$85.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.72727272727273,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$56.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,78.5,105,131.5,158],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.64,56.05230769230769,58.464615384615385,60.87692307692308,63.28923076923077,65.70153846153846,68.11384615384615,70.52615384615385,72.93846153846154,75.35076923076923,77.76307692307692,80.17538461538462,82.58769230769231,{"y":85,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.64,54.723636363636366,55.80727272727273,56.89090909090909,57.974545454545456,59.05818181818182,60.14181818181819,61.225454545454554,62.30909090909091,63.39272727272728,64.47636363636364,65.56,66.64363636363638,{"y":67.72727272727273,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.64,53.82153846153846,54.003076923076925,54.184615384615384,54.36615384615385,54.54769230769231,54.72923076923077,54.91076923076923,55.09230769230769,55.27384615384615,55.45538461538462,55.636923076923075,55.81846153846154,{"y":56,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":157.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.34,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.64,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$85.00Average Price Target$67.73Lowest Price Target$56.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on INSP
Richard Newitter
Truist Financial
Truist Financial
$70→$64
Hold
11.13%
Upside
Reiterated
04/15/26
Inspire Medical price target lowered to $64 from $70 at TruistInspire Medical price target lowered to $64 from $70 at Truist
RBC Capital Analyst forecast on INSP
Shagun Singh Chadha
RBC Capital
RBC Capital
$68→$56
Hold
-2.76%
Downside
Reiterated
04/14/26
Inspire Medical price target lowered to $56 from $68 at RBC CapitalInspire Medical price target lowered to $56 from $68 at RBC Capital
Mizuho Securities Analyst forecast on INSP
Anthony Petrone
Mizuho Securities
Mizuho Securities
$77→$70
Buy
21.55%
Upside
Assigned
04/13/26
Inspire Medical price target lowered to $70 from $85 at MizuhoInspire Medical price target lowered to $70 from $85 at Mizuho
Stifel Nicolaus Analyst forecast on INSP
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$85→$70
Buy
21.55%
Upside
Assigned
04/10/26
Stifel Nicolaus Reaffirms Their Buy Rating on Inspire Medical Systems (INSP)
Evercore ISI Analyst forecast on INSP
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
$85→$62
Buy
7.66%
Upside
Assigned
04/06/26
Inspire Medical price target lowered to $62 from $85 at Evercore ISIInspire Medical price target lowered to $62 from $85 at Evercore ISI
KeyBanc Analyst forecast on INSP
Brett Fishbin
KeyBanc
KeyBanc
―
Hold
―
Reiterated
03/16/26
CMS update 'directionally positive' for Inspire Medical, says KeyBancCMS update 'directionally positive' for Inspire Medical, says KeyBanc
Morgan Stanley Analyst forecast on INSP
Patrick Wood
Morgan Stanley
Morgan Stanley
$130→$60
Hold
4.18%
Upside
Reiterated
02/19/26
Inspire Medical price target lowered to $60 from $130 at Morgan StanleyInspire Medical price target lowered to $60 from $130 at Morgan Stanley
Wolfe Research Analyst forecast on INSP
Michael Polark
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
02/13/26
Inspire Medical downgraded to Peer Perform from Outperform at Wolfe ResearchInspire Medical downgraded to Peer Perform from Outperform at Wolfe Research
UBS Analyst forecast on INSP
Danielle Antalffy
UBS
UBS
$89→$67
Hold
16.34%
Upside
Reiterated
02/13/26
Inspire Medical price target lowered to $67 from $89 at UBSInspire Medical price target lowered to $67 from $89 at UBS
Piper Sandler Analyst forecast on INSP
Adam Maeder
Piper Sandler
Piper Sandler
$165→$85
Buy
47.60%
Upside
Reiterated
02/12/26
Analysts Offer Insights on Healthcare Companies: Doximity (NYSE: DOCS), Atricure (NASDAQ: ATRC) and Inspire Medical Systems (NYSE: INSP)
Nephron Analyst forecast on INSP
Christopher Pasquale
Nephron
Nephron
―
Hold
―
Downgraded
02/12/26
Inspire Medical downgraded to Hold from Buy at Nephron ResearchInspire Medical downgraded to Hold from Buy at Nephron Research
J.P. Morgan Analyst forecast on INSP
Robbie Marcus
J.P. Morgan
J.P. Morgan
$118→$67
Hold
16.34%
Upside
Reiterated
02/12/26
Inspire Medical price target lowered to $67 from $118 at JPMorganInspire Medical price target lowered to $67 from $118 at JPMorgan
Robert W. Baird Analyst forecast on INSP
David Rescott
Robert W. Baird
Robert W. Baird
$130→$74
Hold
28.49%
Upside
Downgraded
02/12/26
Inspire Medical downgraded to Neutral from Outperform at BairdInspire Medical downgraded to Neutral from Outperform at Baird
Wells Fargo Analyst forecast on INSP
Larry Biegelsen
Wells Fargo
Wells Fargo
$145→$70
Hold
21.55%
Upside
Downgraded
02/11/26
Inspire Medical downgraded to Equal Weight from Overweight at Wells FargoInspire Medical downgraded to Equal Weight from Overweight at Wells Fargo
Oppenheimer Analyst forecast on INSP
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Downgraded
01/22/26
Inspire Medical downgraded to Perform from Outperform at OppenheimerInspire Medical downgraded to Perform from Outperform at Oppenheimer
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on INSP
Richard Newitter
Truist Financial
Truist Financial
$70→$64
Hold
11.13%
Upside
Reiterated
04/15/26
Inspire Medical price target lowered to $64 from $70 at TruistInspire Medical price target lowered to $64 from $70 at Truist
RBC Capital Analyst forecast on INSP
Shagun Singh Chadha
RBC Capital
RBC Capital
$68→$56
Hold
-2.76%
Downside
Reiterated
04/14/26
Inspire Medical price target lowered to $56 from $68 at RBC CapitalInspire Medical price target lowered to $56 from $68 at RBC Capital
Mizuho Securities Analyst forecast on INSP
Anthony Petrone
Mizuho Securities
Mizuho Securities
$77→$70
Buy
21.55%
Upside
Assigned
04/13/26
Inspire Medical price target lowered to $70 from $85 at MizuhoInspire Medical price target lowered to $70 from $85 at Mizuho
Stifel Nicolaus Analyst forecast on INSP
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$85→$70
Buy
21.55%
Upside
Assigned
04/10/26
Stifel Nicolaus Reaffirms Their Buy Rating on Inspire Medical Systems (INSP)
Evercore ISI Analyst forecast on INSP
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
$85→$62
Buy
7.66%
Upside
Assigned
04/06/26
Inspire Medical price target lowered to $62 from $85 at Evercore ISIInspire Medical price target lowered to $62 from $85 at Evercore ISI
KeyBanc Analyst forecast on INSP
Brett Fishbin
KeyBanc
KeyBanc
―
Hold
―
Reiterated
03/16/26
CMS update 'directionally positive' for Inspire Medical, says KeyBancCMS update 'directionally positive' for Inspire Medical, says KeyBanc
Morgan Stanley Analyst forecast on INSP
Patrick Wood
Morgan Stanley
Morgan Stanley
$130→$60
Hold
4.18%
Upside
Reiterated
02/19/26
Inspire Medical price target lowered to $60 from $130 at Morgan StanleyInspire Medical price target lowered to $60 from $130 at Morgan Stanley
Wolfe Research Analyst forecast on INSP
Michael Polark
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
02/13/26
Inspire Medical downgraded to Peer Perform from Outperform at Wolfe ResearchInspire Medical downgraded to Peer Perform from Outperform at Wolfe Research
UBS Analyst forecast on INSP
Danielle Antalffy
UBS
UBS
$89→$67
Hold
16.34%
Upside
Reiterated
02/13/26
Inspire Medical price target lowered to $67 from $89 at UBSInspire Medical price target lowered to $67 from $89 at UBS
Piper Sandler Analyst forecast on INSP
Adam Maeder
Piper Sandler
Piper Sandler
$165→$85
Buy
47.60%
Upside
Reiterated
02/12/26
Analysts Offer Insights on Healthcare Companies: Doximity (NYSE: DOCS), Atricure (NASDAQ: ATRC) and Inspire Medical Systems (NYSE: INSP)
Nephron Analyst forecast on INSP
Christopher Pasquale
Nephron
Nephron
―
Hold
―
Downgraded
02/12/26
Inspire Medical downgraded to Hold from Buy at Nephron ResearchInspire Medical downgraded to Hold from Buy at Nephron Research
J.P. Morgan Analyst forecast on INSP
Robbie Marcus
J.P. Morgan
J.P. Morgan
$118→$67
Hold
16.34%
Upside
Reiterated
02/12/26
Inspire Medical price target lowered to $67 from $118 at JPMorganInspire Medical price target lowered to $67 from $118 at JPMorgan
Robert W. Baird Analyst forecast on INSP
David Rescott
Robert W. Baird
Robert W. Baird
$130→$74
Hold
28.49%
Upside
Downgraded
02/12/26
Inspire Medical downgraded to Neutral from Outperform at BairdInspire Medical downgraded to Neutral from Outperform at Baird
Wells Fargo Analyst forecast on INSP
Larry Biegelsen
Wells Fargo
Wells Fargo
$145→$70
Hold
21.55%
Upside
Downgraded
02/11/26
Inspire Medical downgraded to Equal Weight from Overweight at Wells FargoInspire Medical downgraded to Equal Weight from Overweight at Wells Fargo
Oppenheimer Analyst forecast on INSP
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Downgraded
01/22/26
Inspire Medical downgraded to Perform from Outperform at OppenheimerInspire Medical downgraded to Perform from Outperform at Oppenheimer
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Inspire Medical Systems

3 Months
xxx
Success Rate
14/23 ratings generated profit
61%
Average Return
+9.11%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +9.11% per trade.
1 Year
Jonathan BlockStifel Nicolaus
Success Rate
11/21 ratings generated profit
52%
Average Return
+28.46%
Copying Jonathan Block's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +28.46% per trade.
2 Years
xxx
Success Rate
11/21 ratings generated profit
52%
Average Return
+57.91%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 52.38% of your transactions generating a profit, with an average return of +57.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INSP Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
9
13
12
7
2
Buy
15
17
12
6
7
Hold
14
14
19
16
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
38
44
43
29
23
In the current month, INSP has received 9 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. INSP average Analyst price target in the past 3 months is 67.73.
Each month's total comprises the sum of three months' worth of ratings.

INSP Financial Forecast

INSP Earnings Forecast

Next quarter’s earnings estimate for INSP is -$0.33 with a range of -$1.02 to -$0.05. The previous quarter’s EPS was $1.65. INSP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year INSP has Performed in-line its overall industry.
Next quarter’s earnings estimate for INSP is -$0.33 with a range of -$1.02 to -$0.05. The previous quarter’s EPS was $1.65. INSP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year INSP has Performed in-line its overall industry.

INSP Sales Forecast

Next quarter’s sales forecast for INSP is $200.04M with a range of $188.90M to $203.70M. The previous quarter’s sales results were $269.08M. INSP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year INSP has Performed in-line its overall industry.
Next quarter’s sales forecast for INSP is $200.04M with a range of $188.90M to $203.70M. The previous quarter’s sales results were $269.08M. INSP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year INSP has Performed in-line its overall industry.

INSP Stock Forecast FAQ

What is INSP’s average 12-month price target, according to analysts?
Based on analyst ratings, Inspire Medical Systems’s 12-month average price target is 67.73.
    What is INSP’s upside potential, based on the analysts’ average price target?
    Inspire Medical Systems has 17.60% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is INSP a Buy, Sell or Hold?
          Inspire Medical Systems has a consensus rating of Moderate Buy which is based on 4 buy ratings, 10 hold ratings and 0 sell ratings.
            What is Inspire Medical Systems’s price target?
            The average price target for Inspire Medical Systems is 67.73. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $85.00 ,the lowest forecast is $56.00. The average price target represents 17.60% Increase from the current price of $57.59.
              What do analysts say about Inspire Medical Systems?
              Inspire Medical Systems’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of INSP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.